Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q3 2024 · 10-Q
Revenue$51.81M$51.81M+57.6% vs Q3 2023 Net Income-$7.17M-$7.17MN/M vs Q3 2023 EPS Diluted-$0.39-$0.39N/M vs Q3 2023 Operating Income$3,143,000+2.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$35,934,000+401.9% Margins · derivedOperating margin6.1%−3.3 pt vs Q3 2023
Net margin-13.8%+17.4 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 8, 2024 · 39 d after period end